NASDAQ · Financial Statements
Lumos Pharma, Inc. (LUMO) Financial Statements
$4.34
NASDAQ: LUMO
Market Cap $37.54M
Overview Financials Dividend Lumos Pharma, Inc. most recently reported annual revenue of $2.0M, a net loss of $34.0M. Revenue grew at an average annual rate of 14.9% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2019 2020 2021 2022 2023 Revenue $1.0M $0 $0 $2.0M $2.0M Operating Profit $-45.0M $-26.0M $-31.0M $-32.0M $-37.0M Net Profit $-43.0M $-6.0M $-30.0M $-31.0M $-34.0M EPS $-10.39 $-0.84 $-3.65 $-3.71 $-4.18 Op Margin -4822.0% -15656.5% -13629.1% -2103.7% -1785.2%
Balance Sheet (USD)
Metric 2019 2020 2021 2022 2023 Total Assets $97.0M $129.0M $100.0M $72.0M $41.0M Total Liabilities $18.0M $12.0M $11.0M $13.0M $13.0M Cash $91.0M $99.0M $95.0M $56.0M $35.0M Borrowings $1.0M $0 $1.0M $0 $1.0M
Cash Flow (USD)
Metric 2019 2020 2021 2022 2023 Operating Cash Flow $-30.0M $-23.0M $-30.0M $-27.0M $-31.0M Investing Cash Flow $0 $117.0M $26.0M $-23.0M $11.0M Financing Cash Flow $0 $0 $0 $-1.0M $-1.0M Net Cash Flow $-30.0M $94.0M $-4.0M $-39.0M $-21.0M Free Cash Flow $-30.0M $-23.0M $-30.0M $-27.0M $-31.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.09 EV / EBITDA -0.08 FCF Yield -82.84% Quick Ratio 5.69 Interest Coverage — Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .